1. Home
  2. TONX vs GANX Comparison

TONX vs GANX Comparison

Compare TONX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TONX

TON Strategy Company

N/A

Current Price

$2.87

Market Cap

136.5M

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.81

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TONX
GANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.5M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TONX
GANX
Price
$2.87
$1.81
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
640.6K
2.1M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.29
N/A
Revenue
$7,760,000.00
N/A
Revenue This Year
$526.82
N/A
Revenue Next Year
$45.45
N/A
P/E Ratio
$0.39
N/A
Revenue Growth
3760.70
N/A
52 Week Low
$1.88
$1.41
52 Week High
$29.77
$4.34

Technical Indicators

Market Signals
Indicator
TONX
GANX
Relative Strength Index (RSI) N/A 30.82
Support Level N/A $2.04
Resistance Level N/A $2.26
Average True Range (ATR) 0.00 0.29
MACD 0.00 -0.12
Stochastic Oscillator 0.00 0.32

Price Performance

Historical Comparison
TONX
GANX

About TONX TON Strategy Company

TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: